Literature DB >> 15972661

Transgenic expression of dominant-negative Fas-associated death domain protein in beta cells protects against Fas ligand-induced apoptosis and reduces spontaneous diabetes in nonobese diabetic mice.

Janette Allison1, Helen E Thomas, Tara Catterall, Thomas W H Kay, Andreas Strasser.   

Abstract

In type 1 diabetes, many effector mechanisms damage the beta cell, a key one being perforin/granzyme B production by CD8(+) T cells. The death receptor pathway has also been implicated in beta cell death, and we have therefore generated NOD mice that express a dominant-negative form of the Fas-associated death domain protein (FADD) adaptor to block death receptor signaling in beta cells. Islets developed normally in these animals, indicating that FADD is not necessary for beta cell development as it is for vasculogenesis. beta cells from the transgenic mice were resistant to killing via the Fas pathway in vitro. In vivo, a reduced incidence of diabetes was found in mice with higher levels of dominant-negative FADD expression. This molecule also blocked signals from the IL-1R in culture, protecting isolated islets from the toxic effects of cytokines and also marginally reducing the levels of Fas up-regulation. These data support a role for death receptors in beta cell destruction in NOD mice, but blocking the perforin/granzyme pathway would also be necessary for dominant-negative FADD to have a beneficial clinical effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972661     DOI: 10.4049/jimmunol.175.1.293

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Viruses and cytotoxic T lymphocytes in type 1 diabetes.

Authors:  Ken T Coppieters; Matthias G von Herrath
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

2.  Beta cells cannot directly prime diabetogenic CD8 T cells in nonobese diabetic mice.

Authors:  James de Jersey; Sarah L Snelgrove; Stephanie E Palmer; Simon A Teteris; Arno Mullbacher; Jacques F A P Miller; Robyn M Slattery
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

Review 3.  Pathogenic mechanisms in type 1 diabetes: the islet is both target and driver of disease.

Authors:  Kate L Graham; Robyn M Sutherland; Stuart I Mannering; Yuxing Zhao; Jonathan Chee; Balasubramanian Krishnamurthy; Helen E Thomas; Andrew M Lew; Thomas W H Kay
Journal:  Rev Diabet Stud       Date:  2012-12-28

4.  Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes.

Authors:  Andrew F Ziolkowski; Sarah K Popp; Craig Freeman; Christopher R Parish; Charmaine J Simeonovic
Journal:  J Clin Invest       Date:  2011-12-19       Impact factor: 14.808

5.  In vivo diabetogenic action of CD4+ T lymphocytes requires Fas expression and is independent of IL-1 and IL-18.

Authors:  Li Wen; Elizabeth A Green; Thomas Stratmann; Anaïs Panosa; Ramon Gomis; Elizabeth E Eynon; Richard A Flavell; Jovita A Mezquita; Conchi Mora
Journal:  Eur J Immunol       Date:  2011-04-13       Impact factor: 5.532

Review 6.  Targeting the pancreatic β-cell to treat diabetes.

Authors:  Amedeo Vetere; Amit Choudhary; Sean M Burns; Bridget K Wagner
Journal:  Nat Rev Drug Discov       Date:  2014-02-14       Impact factor: 84.694

Review 7.  Apoptosis in pancreatic β-islet cells in Type 2 diabetes.

Authors:  Tatsuo Tomita
Journal:  Bosn J Basic Med Sci       Date:  2016-05-22       Impact factor: 3.363

Review 8.  T cells in the pathogenesis of type 1 diabetes.

Authors:  Roberto Mallone; Peter van Endert
Journal:  Curr Diab Rep       Date:  2008-04       Impact factor: 4.810

9.  Langerhans cells are not required for the CD8 T cell response to epidermal self-antigens.

Authors:  Laura S Bursch; Benjamin E Rich; Kristin A Hogquist
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

10.  Islet beta-cells deficient in Bcl-xL develop but are abnormally sensitive to apoptotic stimuli.

Authors:  Emma M Carrington; Mark D McKenzie; Elisa Jansen; Michelle Myers; Stacey Fynch; Cameron Kos; Andreas Strasser; Thomas W Kay; Clare L Scott; Janette Allison
Journal:  Diabetes       Date:  2009-07-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.